Showing 571-580 of 7719 results for "".
Merz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.In-Review: Two New Melanoma Agents Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/in-review-two-new-melanoma-agents-approved/21534/Utilizing genetic abnormalities, new therapies are carving out new possibilities for melanoma treatment.Skin Resurfacing, Pixel RF from Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/-skin-resurfacing-pixel-rf-from-alma-lasers/19241/Skin resurfacing with the innovative Pixel RF from Alma Lasers. Ready to fight the hands of time? Click here for more info: http://www.AlmaLasers.comVShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologyFrom Clinic to Capitol: Tips for Building Grassroots and Legislative Support For Anti-Tanning Policies in Your State
https://practicaldermatology.com/topics/skin-cancer-photoprotection/from-clinic-to-capitol-tips-for-building-grassroots-and-legislative-support-for-anti-tanning-policies-in-your-state/22943/It's no easy task to shepherd legislation through state assemblies, but dermatologists' clinical standing can have some influence.Ask Me Anything: Mona Sadeghpour, MD
https://practicaldermatology.com/youngmd-connect/wrap-ups/ask-me-anything-mona-sadeghpour-md/24215/An intimate YoungMD Connect virtual mentorship event encourages exchange of ideas, advice, and feedback.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Treating Severe Acne in Transgender Patients: An Update
https://practicaldermatology.com/columns/clinical-focus-1/treating-severe-acne-in-transgender-patients-an-update/23472/Understanding the implications of isotretinoin use in FTM acne patients.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Is this the Golden Age of Hair Loss Treatment?
https://practicaldermatology.com/topics/hair-nails/is-this-the-golden-age-of-hair-loss-treatment/24036/A perfect storm of many new, unrelated scientific developments also has the potential to fundamentally reshape the way we think about a disease or disease group. Dr. Peter C. Friedman believes many recent breakthroughs have profoundly changed how general dermatologists can manage patients with hair